Hypothesis: How do JAK2-inhibitors work in myelofibrosis

Ruben Mesa, Robert Peter Gale

Research output: Contribution to journalComment/debatepeer-review

9 Scopus citations


JAK2-inhibitors rapidly reduce spleen enlargement and clinical symptoms in persons with myelofibrosis but have little, if any, effect on the WBC, anemia, decreased platelets or bone marrow fibrosis. Also, JAK2-inhibitors are active in persons with and without the JAK2-mutation. Based on these and other data we suggest that the predominant effect of JAK2-inhibitors in persons with myelofibrosis is on normal rather than the abnormal clones.

Original languageEnglish (US)
Pages (from-to)1156-1157
Number of pages2
JournalLeukemia Research
Issue number9
StatePublished - Sep 2009


  • JAK2
  • JAK2-inhibitors
  • Myelofibrosis
  • Myeloproliferative disorders
  • Myeloproliferative neoplasms

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research


Dive into the research topics of 'Hypothesis: How do JAK2-inhibitors work in myelofibrosis'. Together they form a unique fingerprint.

Cite this